Protagonist Therapeutics Files 2024 10-K
Ticker: PTGX · Form: 10-K · Filed: Feb 21, 2025 · CIK: 1377121
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
Protagonist Therapeutics filed its 2024 10-K, detailing financials for the year ending Dec 31, 2024.
AI Summary
Protagonist Therapeutics, Inc. filed its 2024 10-K on February 21, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, incorporated in Delaware, is focused on pharmaceutical preparations. Key financial details and operational highlights for the period are detailed within the filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Protagonist Therapeutics' financial health and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Protagonist Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 20250221 (date) — Filing date
- Newark, CA (location) — Company business address
FAQ
What was Protagonist Therapeutics' revenue from contracts with customers for the fiscal year ended December 31, 2024?
The filing indicates 'RevenueFromContractWithCustomerIncludingAssessedTax' for the fiscal year ended December 31, 2024, but a specific dollar amount is not provided in this excerpt.
What is the company's Standard Industrial Classification (SIC) code?
Protagonist Therapeutics, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.
When was Protagonist Therapeutics, Inc. incorporated?
The company was incorporated in Delaware (DE).
What were the key financial activities related to 'AdditionalPaidInCapital' in 2023?
The filing mentions 'PublicOfferingsMember' and 'AtMarketingOfferingMember' in relation to 'AdditionalPaidInCapital' for the period from January 1, 2023, to December 31, 2023.
What is the company's primary business address?
The company's business address is 7707 Gateway Blvd., Suite 140, Newark, CA 94560-1160.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 21, 2025 regarding Protagonist Therapeutics, Inc (PTGX).